Aleksander Chojecki, MD
Hematology · Charlotte, NCNPI 1780997585
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,405 of the $12,876 with a category attached, or 80.8%. 7 manufacturers reported payments, led by Servier Pharmaceuticals LLC at 42.9% of the total. Reporting peaked in 2022 at $7,270 and has fallen 66.1% since, to $2,462 in 2023. That places this record below the midpoint for hematology clinicians in NC, where the typical reported total is $12,876.
Across 25 payments — averaging $515.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Servier Pharmaceuticals LLC$6K
- Novartis$3K
- CTI Biopharma Corp.$2K
- Morphosys, US Inc.$2K
- CSL Behring$125
- Rigel Pharmaceuticals, Inc.$122
- plus $19 from 1 others
Across 27 payments — averaging $9029.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$183K
- E.r. Squibb & Sons, L.L.C.$26K
- National Marrow Donor Program$24K
- Incyte Corporation$11K
What the payments were for
- Consulting fees$10,40581%
- Travel & lodging$1,32210%
- Food & beverage$1,1379%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Servier Pharmaceuticals LLC | 8 | $5,528 |
| Novartis | 10 | $3,010 |
| CTI Biopharma Corp. | 2 | $2,462 |
| Morphosys, US Inc. | 2 | $1,610 |
| CSL Behring | 1 | $125 |
| Rigel Pharmaceuticals, Inc. | 1 | $122 |
| Taiho Oncology, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,876 in reported general payments places this provider in the 50th percentile of 65 hematology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 76 | $1,187,818 |
| OnuregAzacitidine | 14 | $335,108 |
| OjjaaraMomelotinib Dihydrochloride | 11 | $314,162 |
| IclusigPonatinib Hcl | 12 | $259,463 |
| SprycelDasatinib | 16 | $228,572 |
| ImbruvicaIbrutinib | 13 | $201,051 |
| CalquenceAcalabrutinib Maleate | 13 | $187,110 |
| BosulifBosutinib | 13 | $59,025 |
| PegasysPeginterferon Alfa-2a | 12 | $26,291 |
| Danazol | 11 | $3,520 |
| Hydroxyurea | 53 | $1,776 |
| Anagrelide Hcl | 11 | $993 |
| Acyclovir | 43 | $621 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $77 |
| Levofloxacin | 13 | $72 |
Paid to pharmacies, not to this prescriber.
Other hematology in Charlotte
- Ryan JacobsCharlotte$1.5M
- Alan Zausner SkarbnikCharlotte$1.1M
- Raymond ThertulienCharlotte$561K
- Ruben MesaCharlotte$384K
- Michael GrunwaldCharlotte$344K
- Nilay ShahCharlotte$228K
- Peter VoorheesCharlotte$157K
- Patricia KropfCharlotte$122K
- Arielle HeekeCharlotte$88K
- Earle BurgessCharlotte$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.